Wnt7a signals through its receptor Fzd7 to activate the planar-cell-polarity pathway and drive the symmetric expansion of satellite stem cells resulting in enhanced repair of skeletal muscle. In differentiated myofibres, we observed that Wnt7a binding to Fzd7 directly activates the Akt/mTOR growth pathway, thereby inducing myofibre hypertrophy. Notably, the Fzd7 receptor complex was associated with Gα s and PI(3)K and these components were required for Wnt7a to activate the Akt/mTOR growth pathway in myotubes. Wnt7a-Fzd7 activation of this pathway was completely independent of IGF-receptor activation. Together, these experiments demonstrate that Wnt7a-Fzd7 activates distinct pathways at different developmental stages during myogenic lineage progression, and identify a non-canonical anabolic signalling pathway for Wnt7a and its receptor Fzd7 in skeletal muscle.
The Wnt family of genes encodes for 19 cysteine-rich, secreted glycoproteins that bind to Frizzled (Fzd) receptors on target cells 1 
.
In canonical Wnt signalling, binding of Wnt proteins to Fzd activates Disheveled (Dsh), leading to the inactivation of glycogen synthase kinase-3β (GSK-3β), a cytoplasmic serine/threonine kinase, which leads to stabilization of β-catenin 2 . In non-canonical Wnt signalling, Wnt proteins bind Fzd and glypican-4, to activate Dsh at the cell membrane, leading to activation of Rho and JNK or stimulation of calcium influx and activation of NFAT, PKC and CamKII. An additional non-canonical Wnt pathway, the planar-cell-polarity (PCP) pathway, plays a role in patterning by instituting polarity of cells within a tissue, such as in the cochlea 3 . Importantly, we recently demonstrated a role for Wnt-PCP signalling in driving symmetric cell divisions of satellite stem cells in adult skeletal muscle by enhancing the planar polarization of stem cells 4 .
During development, Wnts are essential for myogenic induction in the paraxial mesoderm [5] [6] [7] . Wnts are also involved in regulating differentiation during muscle fibre development 8 , and during muscle regeneration in adults 9, 10 . In the adult, canonical Wnt/β-catenin signalling has been suggested to control myogenic lineage progression by limiting Notch signalling and thus promoting differentiation 11 .
Satellite stem cells represent a small subpopulation of satellite cells that are capable of self-renewal and long-term reconstitution of the satellite cell niche following transplantation 12 . Notably, Wnt7a exposure markedly stimulates the symmetric expansion of satellite stem cells and this expansion requires Fzd7 and Vangl2, both components of the PCP signalling pathway 4 . Wnt7a deficiency results in impaired maintenance of the satellite cell compartment. Therefore, Wnt7a signalling through the PCP pathway controls the homeostatic level of satellite stem cells and hence regulates the regenerative potential of muscle 4 .
IGF-IGFR activation of Akt/mTOR represents the key signalling axis regulating skeletal muscle hypertrophy 13 . Binding of IGF1 to the IGF receptor (IGFR) directly actives phosphatidylinositol-3-OH kinase (PI(3)K) and subsequently Akt. Activation of Akt promotes protein synthesis by inducing the mTOR complex1 and inhibiting GSK3β. The mTORC1 complex stimulates phosphorylation of ribosomal protein S6, which results in enhanced protein translation initiation and elongation. Activation of this pathway has the dual ability to inhibit proteolytic degradation and to stimulate new protein synthesis 13 .
Overexpression of Wnt7a during muscle regeneration results in a marked enhancement of the regeneration process, generating increased numbers of larger fibres, independent of an effect on myoblast proliferation or differentiation 4 . Here, we investigate the activity of Wnt7a on postmitotic muscle fibres and identify an undescribed non-canonical Wnt-Fzd7 signalling pathway that directly activates the anabolic Akt/mTOR hypertrophy pathway.
We reasoned that Wnt7a was inducing hypertrophy of myofibres as tibialis anterior muscle electroporated with a CMV-Wnt7a plasmid showed an increase in mass and myofibre calibre 4 . To investigate whether Wnt7a was in fact stimulating hypertrophic growth of myofibres, we first treated differentiating cultures of satellite-cellderived primary myoblasts with recombinant Wnt7a. After 5 days of differentiation, we observed a significant increase in myotube diameter (p) Wnt7a stimulated an expansion in the satellite cell pool, whereas IGF did not. n = 4. (q) Wnt7a and IGF injection resulted in a significant increase in fibre calibre. n = 4, * P < 0.01, * * P < 0.001, * * * P < 0.0001. NS, not significant. Error bars represent s.e.m.
( Fig. 1a-c) . Similarly, differentiated C2C12 myotubes stably transfected with a CMV-Wnt7a-HA plasmid exhibited enhanced myotube diameters ( Fig. 1e -g). Only application of Wnt7a, but not Wnt5a or Wnt3a, resulted in myofibre hypertrophy ( Fig. 1h and Supplementary  Fig. S1e-h ), underscoring the specificity of the response to Wnt7a. The Wnt7a-treated myotubes also exhibited an increase of about threefold in the numbers of myonuclei ( Supplementary Fig. S1a ).
To discriminate between induction of hypertrophy and enhanced fusion, recombinant Wnt7a was applied to myotubes after 3 days of differentiation. We observed an identical degree of hypertrophy ( Fig. 1d and Supplementary Fig. S1b ). Furthermore, myotubes were treated with Wnt7a after application of cytosine arabinoside 14, 15 (AraC), an inhibitor of DNA replication, to eliminate mononuclear myoblasts. Notably, myotubes in AraC-treated cultures similarly displayed enhanced myofibre diameter ( Supplementary Fig. S1k -m). We next investigated the possibility that Wnt7a accelerates differentiation or enhances proliferation. Western blot and messenger RNA analyses revealed normal kinetics of various myogenic markers ( Supplementary  Fig. S1i,j) . Finally, the rate of proliferation of primary myoblasts 4 , or of C2C12 myoblasts, was not affected ( Supplementary Fig. S1d ). Therefore, we conclude that Wnt7a acts on already established myotubes to induce hypertrophy and is not a consequence of accelerated kinetics of differentiation or enhanced myoblast proliferation.
Electroporation of plasmid CMV-Wnt7a into the tibialis anterior muscle of adult muscle stimulates both satellite cell expansion and myofibre growth to induce productive hypertrophy 4 . Electroporation with CMV-Wnt3a and CMV-Wnt5a expression plasmids did not induce hypertrophy, providing further support for the specificity of the Wnt7a response ( Fig. 1k ). However, the electroporation conditions used also result in an injury to the muscle, raising the question of whether active regeneration is required for the Wnt7a response.
To address whether Wnt7a is capable of stimulating productive hypertrophy with minimal induction of regeneration as compared with electroporation, recombinant Wnt7a protein was directly injected into the tibialis anterior muscles of 7-week-old mice (n = 4). The maximum response occurred after injection of 2.5 µg of Wnt7a, with the mass of the tibialis anterior muscle significantly increased by more than 40% (P < 0.001; Fig. 1o ). Moreover, the numbers of satellite cells were also significantly increased by almost twofold per field (P < 0.001; Fig. 1p ) as well as the fibre calibre ( Fig. 1m ,n,q). Interestingly, the entire muscle was affected, indicating that the injected Wnt7a protein was distributed throughout the muscle. Although IGF injection enhanced muscle mass bilaterally, IGF had no effect on the number of satellite cells ( Fig. 1p ).
Taken together, these data indicate that Wnt7a protein delivered by intramuscular injection results in an increased number of satellite cells together with sustained muscle hypertrophy that is independent of extensive regeneration. Fzd7 is required for the induction of symmetric satellite stem cell divisions by Wnt7a (ref. 4). Co-immunoprecipitation experiments confirmed the binding of Wnt7a to Fzd7 in cultured myotubes ( Supplementary Fig. S2a ) and in COS cells ( Supplementary Fig. S2b ). Wnt7a-HA co-immunoprecipitated specifically with Fzd7-YFP, but not with Fzd3-YFP or YFP alone. Therefore, we investigated whether Fzd7 was also required for the induction of hypertrophy by Wnt7a. Transfection of Fzd7 short interfering RNA (siRNA) resulted in a complete abrogation of the ability of Wnt7a to induce myotube hypertrophy ( Fig. 2a and Supplementary Fig. S2e ). Overexpression of Fzd7 has previously been demonstrated to activate downstream signalling 16 . Interestingly, we observed that overexpression of Fzd7 was sufficient to induce hypertrophy in myotubes derived from both C2C12 myoblasts ( Fig. 2b,d ,e) and primary myoblasts ( Fig. 2c,f,g) .
The PCP effector Vangl2 is required for Wnt7a induction of symmetric satellite stem cell divisions 4 . Knockdown of Vangl2 did not interfere with Wnt7a induction of myotube hypertrophy (Supplementary Fig. S2d ,g). However, Vangl2 is strongly downregulated through myogenic differentiation (not shown). Therefore, we conclude that PCP signalling is not involved in the induction of myotube hypertrophy by Wnt7a-Fzd7.
Wnt7a has been implicated in both canonical and non-canonical Wnt signalling depending on the cell and tissue context 4, 17 . Previously, we demonstrated that Wnt7a stimulation of myogenic cells did not result in upregulation of Tcf7 or Axin2 or activation of β-catenin 6 . Therefore, to confirm that Wnt7a was acting through the non-canonical pathway in differentiated muscle, we assessed the degree of GSK3β and βcatenin phosphorylation by immunoblot analyses. Wnt7a stimulation of differentiated myotubes resulted in no change in the levels or phosphorylation of these canonical Wnt signalling components Supplementary Fig. S2i -k). Together, these data unequivocally demonstrate that Wnt7a is acting through a non-canonical signalling pathway to induce myofibre hypertrophy.
The central signalling pathway implicated in the regulation of myofibre hypertrophy in skeletal muscle is the Akt/mTOR pathway 13 . Therefore, we assessed the ability of Wnt7a to activate Akt/mTOR signalling. Strikingly, we observed that Wnt7a treatment resulted in markedly elevated levels of phosphorylated Akt and its downstream target S6 in cultured myotubes (Fig. 3a,c and Supplementary Fig. S3e -j). Importantly, Wnt7a treatment of proliferating myoblasts did not activate the Akt/mTOR pathway ( Fig. 3a ). Neither Wnt3a nor Wnt5a activated Akt or S6 ( Supplementary Fig. S4d ). A single injection of recombinant Wnt7a into excised tibialis anterior muscles resulted in robust activation of Akt and S6 ( Fig. 3b ). Inhibition of mTOR by rapamycin completely blocked the induction of hypertrophy by Wnt7a without affecting myoblast fusion ( Fig. 3d and Supplementary  Fig. S4a-c) . Foxo transcription factors are key effectors of the Akt/mTOR growth pathway in skeletal muscle 13 . Accordingly, we observed inhibitory phosphorylation of the Akt downstream targets Foxo1 and Foxo3a following Wnt7a stimulation ( Fig. 3a) .
To evaluate the involvement of other non-canonical Wnt signalling pathways, we investigated the phosphorylation of PKC, CamKII and c-Jun, the downstream effector of JNK ( Fig. 3a ). None of these components was significantly activated in Wnt7a-HA-expressing C2C12 cells during differentiation or after application of Wnt7a to myotubes ( Supplementary Fig. S4e ). Together, these data strongly support the assertion that Wnt7a acts on muscle fibres through activation of the anabolic Akt/mTOR signalling pathway.
In skeletal muscle, IGF1 and its muscular isoform MGF are ligands of the IGFR, which signals through IRS1 to activate the PI(3)K/Akt/mTOR growth pathway 13 . We therefore investigated the possibility that Wnt7a was indirectly activating the Akt/mTOR pathway by inducing an upregulation of IGF1 expression. C2C12 myotubes treated with recombinant Wnt7a protein did not show any increase in the level of phosphorylated IGFR, but showed a robust phosphorylation of Akt and S6 ( Fig. 3c ). Western blot analyses using phospho-specific antibodies indicated that Wnt7a stimulation had no effect on the activation of IGFR or IRS1 ( Fig. 4a and Supplementary Fig. S4f ,g). Specific inhibition of IGFR using AG1024 (ref. 19 ) did not prevent stimulation of myotube hypertrophy by Wnt7a ( Fig. 4b ), although AG1024 treatment resulted in smaller myotubes in control cells as expected. Furthermore, examination of Igf1 and Mgf mRNA levels revealed that these genes were in fact downregulated following Wnt7a stimulation (Fig. 4c ). Therefore, we conclude that Wnt7a induces hypertrophy independent of IGFR/IRS1 activity. In skeletal muscle, phosphorylation of PI(3)K directly activates the Akt/mTOR hypertrophic pathway 20, 21 . Notably, we observed increased phosphorylation of PI(3)K following Wnt7a induction of cultured myotubes (Fig. 3a) . Therefore, to investigate whether Fzd7 was directly activating the PI(3)K/Akt/mTOR pathway, we carried out coimmunoprecipitation experiments to assess the potential association of Fzd7 and PI(3)K in a receptor complex. Strikingly, PI(3)K was detected by western blot following immunoprecipitation of Fzd7, but not Fzd3, from extracts prepared from myotubes (Fig. 5a ). Importantly, this interaction was not detectable in proliferating myoblasts (Fig. 5a ). Treatment of the cells with the specific PI(3)K inhibitor LY294002 completely abrogated the ability of Wnt7a to induce myotube hypertrophy (Fig. 5b) . Therefore, we conclude that a myotube-specific receptor complex, containing Fzd7 and PI(3)K, mediates the activation of the Akt/mTOR growth pathway following Wnt7a stimulation.
We carried out mass spectrometry to identify additional components of the Fzd7 receptor complex in myotubes. These experiments identified the G protein subunit α S (stimulatory G protein, Gα s ) as an Fzd7-associated protein. Binding of Fzd7 to Gα s (encoded by the GNAS1 gene) was confirmed by co-immunoprecipitation analyses in myotubes of C2C12 cells. Gα s specifically bound Fzd7-YFP but not YFP alone (Fig. 5c ). These data led us to reason that Gα s mediates the activation of PI(3)K following Wnt7a binding to Fzd7. Therefore, we investigated whether differentiated myotubes treated with suramin, a specific inhibitor of the association of Gα s and β-γ subunits 22, 23 , was capable of abrogating Wnt7a-induced hypertrophy. Strikingly, suramin completely blocked Wnt7a-induced hypertrophy and phosphorylation of Akt and S6 (Fig. 5d,e ), but did not inhibit IGF1-induced hypertrophy ( Supplementary Fig. S4j ). Furthermore, knockdown of Gα s (Supplementary Fig. S4k ) resulted in abrogation of Wnt7a-induced hypertrophy ( Fig. 5f ). Taken together, these data unequivocally establish that the Wnt receptor Fzd7, and the associated components Gα s and PI(3)K, are required for the induction of myotube hypertrophy by Wnt7a.
We have described a role for Wnt signalling in the direct regulation of growth pathways in differentiated skeletal muscle. Binding of Wnt7a to Fzd7 directly activated PI(3)K and the Akt/mTOR pathway to induce myofibre hypertrophy both in vitro and in vivo. Strikingly, Wnt7a-Fzd7 activation of the PI(3)K/Akt/mTOR pathway was independent of IGFR activation. Therefore, we have identified a so far undescribed non-canonical anabolic pathway for Wnt7a and its receptor Fzd7 in skeletal muscle.
Our results indicate that Wnt7a acts through distinct non-canonical pathways at two cellular levels in skeletal muscle: through PCP signalling in satellite cells to regulate their homeostatic levels 4 ; and through the Akt/mTOR pathway in differentiated myofibres to regulate growth (summarized in Supplementary Fig. S5 ). In this manner, Wnt7a functions to couple the expansion of the satellite cell pool to the mass of the muscle tissue. Loss of Wnt7a results in reduced numbers of satellite cells 3 weeks after injury 4 , thus demonstrating the physiological role of Wnt7a in regulating the homeostatic levels of satellite cells. Therefore, we predict that the dual function of Wnt7a in skeletal muscle has a role in the adaptation of muscle to different physiological stimuli. We previously described a role for Wnt7a-Fzd7 signalling in satellite stem cells dependent on the PCP component Vangl2 (ref. 4) . In contrast, we found that Wnt7a-Fzd7 activation of the Akt/mTOR pathway in differentiated skeletal muscle was independent of Vangl2. Moreover, we observed that Gα s and PI(3)K were associated with the Fzd7 receptor complex specifically in differentiated myotubes, and not in proliferating myoblasts. These data therefore indicate that the Fzd7 receptor complex contains distinct components in satellite cells versus differentiated myofibres.
The presence of seven transmembrane domains in Fzd receptors is reminiscent of the structure of classical G protein receptors 24 . Frizzled proteins are considered a unique and separate family of G-coupled receptors 25 . Therefore, we speculated that the Fzd7 receptor complex in myotubes contains additional factors such as G proteins that are required to activate PI(3)K. Through mass spectrometry analyses we found the following G protein subunits associated with Fzd7: G protein α S (Gα s , encoded by the GNAS1 gene), G protein β1, G protein β2 and the G protein subunit O. We chose to investigate the function of Gα s because the GNAS1 gene is expressed at a high level during differentiation of C2C12 cells (see Supplementary Fig. S4h,i) .
Heteromeric G proteins consist of an α subunit that is regulated by guanine-nucleotide binding and the tightly associated β-γ subunit. Depending on the G protein family involved, the α and β-γ subunits can activate diverse effectors. Our results indicate that Wnt7a activates the Gα s protein, thereby leading to an activation of PI(3)K, presumably through a Gβγ complex involving G protein β1 or β2.
In differentiated myofibres, Wnt7a binds to Fzd7, resulting in the activation of PI(3)K, which in turn activates phosphatidyl inositoldependent kinase 1 (PDK1). PDK1 then activates Akt, leading to the activation of its downstream targets S6 kinase and S6 and the induction of hypertrophy 26, 27 . Thus, Wnt7a binding to its Fzd7 receptor complex containing Gα s and PI(3)K activates the Akt/mTOR growth pathway in muscle entirely independently of IGF and IGFR.
Akt has the dual potential to drive the synthesis of protein while preventing proteolytic degradation. This makes Akt a key metabolic control point in diseases that are characterized by changes in muscle mass, for example cancer cachexia and sarcopenia 28, 29 . Other catabolic states such as malnutrition, critical illness and sepsis are associated with a profound reduction in the pool of IGF1 resulting in muscle atrophy 27, 30 . Consequently, IGF1 treatment has been explored as a potential treatment to increase the lean body mass in patients suffering from these conditions 31 . However, limitation of this approach arises from the development of resistance to growth hormones and to the development of hypoglycaemia 32 .
Muscle damage due to eccentric exercise as well as cachexia induces TNFα expression. This cytokine markedly impairs insulin stimulation of IRS1 (refs 33,34) . It is believed that TNFα induces insulin resistance in skeletal muscle by activation of IKK, which then phosphorylates IRS1, thereby precluding subsequent activation of PI(3)K and Akt (ref. 35 ). Wnt7a activates the PI(3)K/Akt/mTOR signalling axis without an activation of IRS1. Therefore, it is interesting to speculate that Wnt7a will be able to induce hypertrophy and/or prevent muscle wasting in the context of high TNFα levels without developing insulin resistance.
Our work has identified an additional non-canonical Wnt signalling pathway to the known variations of canonical and non-canonical pathways. The Wnt anabolic signalling pathway, where Wnt7a activates the Fzd7/PI(3)K/Akt/mTOR hypertrophy pathway, provides a promising new therapeutic focus for the amelioration of muscle wasting diseases such as sarcopenia, cachexia or muscular dystrophies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology Note: Supplementary Information is available on the Nature Cell Biology website 40 µg of plasmid DNA in 0.9% NaCl was injected directly into the right tibialis anterior muscle of anaesthetized male C57BL/6 mice (10 weeks of age). Immediately after injection of the plasmid, electric stimulation was applied directly to the tibialis anterior muscle using a pulse generator (ECM 830, BTX) equipped with 5 mm needle electrodes to generate six 100 V pulses, with a fixed duration of 20 ms and an interval of 200 ms between the pulses. Experimental and contralateral muscles were isolated and embedded in OCT/10% sucrose (Tissue-Tec) and cooled with liquid nitrogen. Cross-sections (14 µm) of the muscle were obtained using a cryostat (Leica CM1850).
To ensure that the same areas of the muscles were compared, we cut the tibialis anterior muscle in the middle of the belly and counted the sections that were used for immunostainings. Protein injections of recombinant Wnt7a protein (R&D Systems) were conducted in a similar fashion to injection of plasmid DNA. Mice were killed 2 weeks after electroporation or protein injection. Adult (10 weeks of age) C57/Bl6 mice were obtained from Charles River. All experiments were carried out following the regulations of the University of Ottawa for animal handling and animal care.
Cell culture and transfection. Mononucleated-muscle-derived cells were isolated from hind-limb muscles of Balb/C mice (4 weeks old), cultured and differentiated as previously described 36 . Cells were sorted by FACS and cultured as previously described 37 . C2C12 myoblasts were cultivated using standard methodology 38 . Recombinant Wnt7a, Wnt3a and Wnt5a (R&D Systems) were administered to the cells in a final concentration of 50 ng ml −1 . Rapamycin (NEB), LY294002 (NEB), AG1024 (EMD Bioscience), AraC (cytosine β-d-arabinofuranoside, Sigma), suramin (Sigma) and BIO (Sigma) were applied in the following final concentrations: rapamycin (20 ng ml −1 ), LY294002 (50 µM), AG1024 (10 µM), (AraC 50 µM), suramin (250 µM), BIO (1 µM). C2C12 cells were transfected with the expression plasmids or siRNA (Ambion) using Lipofectamine 2000 (Roche) according to instructions provided by the manufacturer.
Protein and RNA analyses. Western and co-immunoprecipitation analyses were carried out as described previously 37,39 . Immunoprecipitation was conducted using
Chromotek-GFP-Trap beads purchased from Allele Biotechnology and Pharmaceuticals according to instructions provided by the manufacturer. Immunofluorescence analyses were carried out as described previously 37 . Nuclei were counterstained with Hoechst as recommended by the manufacturer. For antibodies used in this study, see Supplementary Table S1 . RNA extraction and quantitative real-time PCR were carried out as described previously 37 . For primers used in this study, see Supplementary Table S2 . Tandem affinity purification and mass spectrometry were carried out as described previously 40 .
Statistical analyses.
A minimum of three up to five replicates were analysed for each experiment presented. Data are presented as the mean ± s.e.m. (Microsoft Excel), and we assessed statistical significance using Student's t test (Microsoft Excel). Differences were considered as statistically significant with a P value <0.01.
Mice and animal care. Adult (10 weeks of age) C57/Bl6 mice were obtained from Charles River. All mice were maintained inside the animal care facility and experiments were carried out following the regulations of the University of Ottawa for animal handling and animal care.
Immunoblot analyses and immunoprecipitation. Immunoblot analyses were carried out as described previously 37 . The following antibodies were obtained from Cell Signaling and used at a concentration recommended by the manufacturer: pan-Akt; Ser473-Akt; pS6; pS6kinase. Antibodies against myogenin and myosin heavy chain were obtained from Santa Cruz; antibodies against tubulin were purchased from Sigma. Immunoprecipitation was conducted using Chromotek-GFP-Trap beads purchased from Allele Biotechnology & Pharmaceuticals according to instructions provided by the manufacturer.
Immunofluorescence microscopy analysis. Immunofluorescence microscopy analyses were carried out as described previously 37 . Antibodies against laminin were obtained from Sigma (1:1,000). Nuclei were counterstained with Hoechst as recommended by the manufacturer. 
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